Read by QxMD icon Read

Ovarian cancer

Federica Alessandrini, Laura Pezzè, Daniel Menendez, Michael A Resnick, Yari Ciribilli
Breast cancer treatment often includes Doxorubicin as adjuvant as well as neoadjuvant chemotherapy. Despite its cytotoxicity, cells can develop drug resistance to Doxorubicin. Uncovering pathways and mechanisms involved in drug resistance is an urgent and critical aim for breast cancer research oriented to improve treatment efficacy. Here we show that Doxorubicin and other chemotherapeutic drugs induce the expression of ETV7, a transcriptional repressor member of ETS family of transcription factors. The ETV7 expression led to DNAJC15 down-regulation, a co-chaperone protein whose low expression was previously associated with drug resistance in breast and ovarian cancer...
July 16, 2018: Neoplasia: An International Journal for Oncology Research
Cheol Keun Park, Douglas P Malinowski, Nam Hoon Cho
This study was conducted to develop a novel algorithm for determining the origin of tumors by combining analysis of cluster patterns with immunocytochemistry (ICC) for markers in cells from fine-needle aspirates of ascites. We used LBC, based on SurePathTM (BD Diagnostics) technology, to screen 96 peritoneal fluid samples from patients with known malignancies and from 10 control patients with cirrhosis. Following dual ICC staining for cytokeratin 7 (CK7) and paired box gene 8 (PAX8), we developed an algorithm using immunoreactivity and three-dimensional (3D) cluster patterns to correlate staining and 3D cluster patterns with common primary origins that included stomach, ovarian, pancreatobiliary tract, colon, lung, and breast cancers...
2018: PloS One
Laurence Booth, Jane Roberts, Andrew Poklepovic, Paul Dent
Inhibitors of PARP1 are approved therapeutic agents in ovarian carcinomas. We determined whether the novel clinically relevant CHK1 inhibitor SRA737 interacted with PARP1 inhibitors to kill carcinoma cells. In multiple mammary and ovarian cancer lines SRA737 synergized with the PARP1 inhibitors olaparib and niraparib to cause cell death. The [SRA737 + niraparib] drug combination activated an ATM-AMPK-ULK1-mTOR pathway which resulted in the formation of autophagosomes, temporally followed by autolysosome formation...
July 19, 2018: Cancer Biology & Therapy
H-B Suo, K-C Zhang, J Zhao
OBJECTIVE: To explore the role of miR-200a combined with PTEN in the progression of ovarian carcinoma. PATIENTS AND METHODS: The human ovarian cancer tissues and normal adjacent tissues (n = 57) were obtained from our hospital. The human ovarian cancer cell lines OVCAR3 and A2780, the human ovarian surface epithelial cell line (HOSEpiC), and HEK293T cells were used in this study. Cell migration assay and invasion assay were used to detect the ability of cell migratory...
July 2018: European Review for Medical and Pharmacological Sciences
Hui-Chen Kuo, Ying Tsao, Hua-You Tu, Zih-Huei Dai, Debra K Creedy
Sleep disturbance is a significant problem affecting around 50% of cancer patients. Non-pharmacological interventions can be used to improve sleep quality in cancer patients, but little is known about the feasibility, acceptability, and effectiveness of auricular point acupressure (APA) to reduce sleep disturbance in women with ovarian cancer undergoing chemotherapy. A pilot randomized controlled trial was conducted at a publicly funded hospital in southern Taiwan. Fifty-five eligible women were approached and 47 women participated...
July 19, 2018: Research in Nursing & Health
Anna Minchom, Caterina Aversa, Juanita Lopez
Maintenance of genomic stability is a critical determinant of cell survival and relies on the coordinated action of the DNA damage response (DDR), which orchestrates a network of cellular processes, including DNA replication, DNA repair and cell-cycle progression. In cancer, the critical balance between the loss of genomic stability in malignant cells and the DDR provides exciting therapeutic opportunities. Drugs targeting DDR pathways taking advantage of clinical synthetic lethality have already shown therapeutic benefit - for example, the PARP inhibitor olaparib has shown benefit in BRCA -mutant ovarian and breast cancer...
2018: Therapeutic Advances in Medical Oncology
Wen-Peng Wang, Ning Li, Yuan-Yuan Zhang, Yu-Tao Gao, Yang-Chun Sun, Li Ge, Ling-Ying Wu
Background: The role that lymph node dissection (LND) plays in the management of ovarian carcinosarcoma (OCS) is unclear due to its rarity. This study investigated lymph node metastasis (LNM) prevalence in women with early OCS and effects of LND and LNM on survival. Methods: Data of women diagnosed with OCS, whose primary tumor was confined to ovaries (American Joint Committee on Cancer [AJCC] T1) or pelvic cavity (AJCC T2), between 1988 and 2010 were collected from the Surveillance, Epidemiology, and End Results (SEER) database...
2018: Cancer Management and Research
Michelle K Wilson, Rebecca Mercieca-Bebber, Michael Friedlander
Health related quality of life (HRQOL) is a key priority for patients with ovarian cancer as there is significant morbidity associated with the disease and the treatment. It is therefore essential to include measures of HRQOL and patient reported outcomes (PROs) in all clinical trials and ideally report them in the initial manuscript. The results of these analyses help interpret the primary trial endpoints which are typically progression free survival and overall survival from the perspective of the patients, but can also assist with regulatory approval of new drugs and inform future patients regarding the potential benefits and downsides of the treatment as well as help support clinical recommendations...
July 9, 2018: Journal of Gynecologic Oncology
Erin A Blake, Madushka Y De Zoysa, Elise B Morocco, Samantha B Kaiser, Michiko Kodama, Brendan H Grubbs, Koji Matsuo
OBJECTIVE: To examine survival of teenage women with pregnancies complicated by primary ovarian cancer. METHODS: This is a secondary analysis of a previously organized systematic literature review of primary ovarian cancer diagnosed during pregnancy. Cases eligible for analysis were patients whose age at cancer diagnosis and survival outcome were known (n=201). Pregnancy and oncologic outcome were then examined based on patient age. RESULTS: These were comprised of 95 (47...
June 27, 2018: Journal of Gynecologic Oncology
Ayaka Iura, Morihito Takita, Aiko Kawano, Kazuaki Imai, Katsuyuki Konnai, Ryo Onose, Hisamori Kato
OBJECTIVE: Optimal debulking in interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) has been reported as a prognostic factor for patients with ovarian cancer. However, the identification of microscopic residual disease (MRD) using visualization and palpation is subjective. Peritoneal washing cytology (PWC) during IDS is an easy-to-implement, objective approach for assessing disease status, although its clinical relevance and association with MRD is not known. The aim of this study was to evaluate the efficacy of PWC during IDS...
May 4, 2018: Journal of Gynecologic Oncology
Koji Matsuo, Hiroko Machida, Andrea Mariani, Rachel S Mandelbaum, Gretchen E Glaser, Bobbie S Gostout, Lynda D Roman, Jason D Wright
OBJECTIVE: To examine the trends and survival for women with early-stage epithelial ovarian cancer who underwent adequate lymphadenectomy during surgical treatment. METHODS: This is a retrospective observational study examining the Surveillance, Epidemiology, End Results program between 1988 and 2013. We evaluated 21,537 cases of stage I-II epithelial ovarian cancer including serous (n=7,466), clear cell (n=6,903), mucinous (n=4,066), and endometrioid (n=3,102) histology...
May 4, 2018: Journal of Gynecologic Oncology
Hirokuni Takano, Keiko Nakajima, Yoko Nagayoshi, Hiromi Komazaki, Jiro Suzuki, Hiroshi Tanabe, Shigeki Niimi, Seiji Isonishi, Aikou Okamoto
OBJECTIVE: Since there have been few large series studies to date, we investigated the relationship between Trousseau's syndrome associated with cerebral infarction and its clinical associations with ovarian cancer. METHODS: In this study, we investigated the association between cerebral infarction onset and ovarian cancer. Eight-hundred twenty-seven consecutive ovarian cancer patients from 4 affiliated academic institutions were included in the study over a 12 years period...
April 23, 2018: Journal of Gynecologic Oncology
Giorgio Bogani, Diego Rossetti, Antonino Ditto, Fabio Martinelli, Valentina Chiappa, Lavinia Mosca, Umberto Leone Roberti Maggiore, Stefano Ferla, Domenica Lorusso, Francesco Raspagliesi
OBJECTIVE: Accumulating evidence support that complete cytoreduction (CC) at the time of secondary cytoreductive surgery (SCS) improves survival in patients affected by recurrent ovarian cancer (ROC). Here, we aimed to determine whether artificial intelligence (AI) might be useful in weighting the importance of clinical variables predicting CC and survival. METHODS: This is a retrospective study evaluating 194 patients having SCS for ROC. Using artificial neuronal network (ANN) analysis was estimated the importance of different variables, used in predicting CC and survival...
April 23, 2018: Journal of Gynecologic Oncology
Zheng Feng, Hao Wen, Zhaoxia Jiang, Shuai Liu, Xingzhu Ju, Xiaojun Chen, Lingfang Xia, Junyan Xu, Rui Bi, Xiaohua Wu
OBJECTIVE: To present the surgical outcomes of advanced epithelial ovarian cancer (AEOC) since the implementation of a personalized approach and to validate multiple predictive models for R0 resection. METHODS: Personalized strategies included: 1) Non-invasive model: preoperative clinico-radiological assessment according to Suidan criteria with a predictive score for all individuals. Patients with a score 0-2 were recommended for primary debulking surgery (PDS, group A), or otherwise were counseled on the choices of PDS, neoadjuvant chemotherapy (NAC, group B) or staging laparoscopy (S-LPS)...
April 23, 2018: Journal of Gynecologic Oncology
Scott Shaw, Wenqi Liu, César Fernando Azael Gómez Durán, Cynthia Schreiber, María de Lourdes Betancourt Mendiola, Canjia Zhai, Felicia Roland, Simon Padanilam, Bradley D Smith
Fluorescent molecular probes were prepared by a programmed non-covalent pre-assembly process that used a near-infrared fluorescent squaraine dye to thread a macrocycle bearing a cancer targeting unit. Cell microscopy studies using OVCAR-4 (ovarian cancer) and A549 (lung cancer) cells that express high levels of the integrin αvβ3 or αvβ5 receptors, respectively, revealed a multivalent cell targeting effect. That is, there was comparatively more cell uptake of a pre-assembled probe equipped with two copies of the cRGDfK antagonist than a pre-assembled probe with only one appended cRGDfK antagonist...
July 18, 2018: Chemistry: a European Journal
Kimiya Sato, Morikazu Miyamoto, Masashi Takano, Kenichi Furuya, Hitoshi Tsuda
The aquaporins (AQPs) are a family of transmembrane water channel proteins that are distributed in various human tissues. Recent studies have suggested that AQP expression correlates with various aspects of cancer biology that determine the aggressiveness of different cancers. Ovarian carcinoma is one of the most lethal gynecological cancers. Some studies have suggested that AQPs are expressed in ovarian carcinoma, and are associated with cancer cell growth and migration. In this study, we immunohistochemically evaluated the expression of AQP1, 3, 5, and 9 in a total of 300 ovarian carcinomas using tissue microarrays...
July 19, 2018: Pathology Oncology Research: POR
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier, Mareike Herzog, Jonathan Lam, Abigail Shea, Mukerrem Demir, Qian Wu, Fengtang Yang, Beiyuan Fu, Zhongwu Lai, Gabriel Balmus, Rimma Belotserkovskaya, Violeta Serra, Mark J O'Connor, Alejandra Bruna, Petra Beli, Luca Pellegrini, Carlos Caldas, Ludovic Deriano, Jacqueline J L Jacobs, Yaron Galanty, Stephen P Jackson
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISPR-Cas9 synthetic-viability/resistance screens in BRCA1-deficient breast cancer cells treated with PARP inhibitors. We identified two previously uncharacterized proteins, C20orf196 and FAM35A, whose inactivation confers strong PARP-inhibitor resistance. Mechanistically, we show that C20orf196 and FAM35A form a complex, 'Shieldin' (SHLD1/2), with FAM35A interacting with single-stranded DNA through its C-terminal oligonucleotide/oligosaccharide-binding fold region...
July 18, 2018: Nature Cell Biology
Ji-Hye Ahn, Tae Jin Kim, Jae Ho Lee, Jung-Hye Choi
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
July 18, 2018: Scientific Reports
Luyao Zhang, Hongyao Yu, Otto Hemminki, Asta Försti, Kristina Sundquist, Kari Hemminki
Familial risks for testicular cancer (TC) are among the highest of all cancers. However, data are limited for histological types of TC and for possible familial associations of TC with other cancers. We used the nationwide Swedish Family-Cancer Database for years 1958 to 2015 to analyse familial relative risks (RR) for 11,138 TC patients when first-degree relatives were diagnosed with TC or other cancer in reference to those without a family history. A total of 191 familial TCs were found, which accounted for 2...
July 18, 2018: Scientific Reports
Yasuaki Kabe, Makoto Suematsu, Satoshi Sakamoto, Miwa Hirai, Ikko Koike, Takako Hishiki, Atsushi Matsuda, Yuichi Hasegawa, Koji Tsujita, Masayuki Ono, Naoko Minegishi, Atsushi Hozawa, Yoshinori Murakami, Michiaki Kubo, Makoto Itonaga, Hiroshi Handa
BACKGROUND: Although circulating exosomes in blood play crucial roles in cancer development and progression, difficulties in quantifying exosomes hamper their application for reliable clinical testing. By combining the properties of nanobeads with optical disc technology, we have developed a novel device named the ExoCounter to determine the exact number of exosomes in the sera of patients with various types of cancer. METHOD: In this system, individual exosomes were captured in the groove of an optical disc coated with antibodies against exosome surface antigens...
July 18, 2018: Clinical Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"